Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria: Patients must meet all of the following inclusion criteria in order to be eligible to participate in this study:
Exclusion Criteria: Patients meeting any of the following exclusion criteria are not eligible to participate in this study:
Primary purpose
Allocation
Interventional model
Masking
276 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Karyopharm Medical Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal